bivalirudin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hirudin derivatives 385 128270-60-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bivalirudin
  • angiomax
  • angiox
  • hirulog
designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition
  • Molecular weight: 2180.32
  • Formula: C98H138N24O33
  • CLOGP:
  • LIPINSKI: 3
  • HAC: 57
  • HDO: 28
  • TPSA: 901.57
  • ALOGS: -4.67
  • ROTB: 66

Drug dosage:

DoseUnitRoute
0.25 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.42 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2000 FDA MEDICINES CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery thrombosis 426.90 61.51 64 1633 1075 63486250
Thrombosis in device 285.74 61.51 52 1645 2938 63484387
Coagulation time abnormal 235.32 61.51 28 1669 59 63487266
Device occlusion 151.99 61.51 36 1661 7351 63479974
Retroperitoneal haemorrhage 132.30 61.51 27 1670 2770 63484555
Heparin-induced thrombocytopenia 129.92 61.51 29 1668 4553 63482772
Cardiac procedure complication 89.08 61.51 13 1684 177 63487148
Thrombosis 87.78 61.51 40 1657 64715 63422610
Coronary artery perforation 82.25 61.51 10 1687 27 63487298
Haemorrhage 71.21 61.51 34 1663 60988 63426337
Coronary artery dissection 69.43 61.51 13 1684 849 63486476
Coagulation time prolonged 68.57 61.51 14 1683 1434 63485891
Cardiac tamponade 66.37 61.51 17 1680 4758 63482567
Coronary artery occlusion 66.13 61.51 19 1678 8172 63479153
Procedural complication 64.18 61.51 17 1680 5422 63481903
Post procedural complication 63.86 61.51 22 1675 17052 63470273
Vascular stent thrombosis 61.63 61.51 12 1685 965 63486360

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombosis in device 512.37 54.38 100 2258 3225 34951348
Coronary artery thrombosis 483.80 54.38 89 2269 2070 34952503
Coagulation time abnormal 356.92 54.38 48 2310 108 34954465
Thrombosis 146.01 54.38 70 2288 50388 34904185
Procedural complication 138.27 54.38 36 2322 4247 34950326
Heparin-induced thrombocytopenia 133.32 54.38 37 2321 5558 34949015
Vascular stent thrombosis 106.07 54.38 27 2331 2908 34951665
Device occlusion 88.80 54.38 28 2330 6517 34948056
Acute myocardial infarction 80.06 54.38 48 2310 53671 34900902
Haemorrhage 74.21 54.38 45 2313 51325 34903248
Haemorrhage intracranial 64.49 54.38 28 2330 15918 34938655
Coronary artery dissection 64.32 54.38 12 2346 297 34954276
Oesophageal ulcer haemorrhage 62.45 54.38 11 2347 195 34954378
Coagulation time prolonged 62.24 54.38 15 2343 1287 34953286
Kounis syndrome 61.53 54.38 17 2341 2501 34952072
Cardiac procedure complication 57.34 54.38 10 2348 167 34954406
Reperfusion injury 57.15 54.38 9 2349 77 34954496
Chest pain 56.39 54.38 55 2303 126707 34827866

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coronary artery thrombosis 660.74 50.97 116 3627 2990 79737655
Thrombosis in device 608.11 50.97 118 3625 5324 79735321
Coagulation time abnormal 441.13 50.97 58 3685 170 79740475
Heparin-induced thrombocytopenia 258.61 50.97 65 3678 9617 79731028
Thrombosis 183.84 50.97 86 3657 84014 79656631
Procedural complication 175.93 50.97 46 3697 7937 79732708
Vascular stent thrombosis 172.42 50.97 39 3704 3671 79736974
Device occlusion 162.31 50.97 47 3696 11819 79728826
Acute myocardial infarction 132.75 50.97 67 3676 76969 79663676
Coagulation time prolonged 114.68 50.97 26 3717 2469 79738176
Haemorrhage 108.51 50.97 62 3681 91056 79649589
Retroperitoneal haemorrhage 108.45 50.97 29 3714 5441 79735204
Coronary artery perforation 107.33 50.97 15 3728 77 79740568
Haemorrhage intracranial 93.79 50.97 38 3705 26155 79714490
Cardiac tamponade 93.31 50.97 29 3714 9247 79731398
Coronary artery dissection 92.61 50.97 19 3724 1125 79739520
Cardiac procedure complication 92.59 50.97 16 3727 370 79740275
Cardiac arrest 85.43 50.97 68 3675 172028 79568617
Ventricular fibrillation 83.31 50.97 37 3706 31889 79708756
Coronary artery occlusion 79.05 50.97 29 3714 15286 79725359
Electrocardiogram ST segment elevation 75.09 50.97 24 3719 8373 79732272
Pulmonary haemorrhage 72.76 50.97 27 3716 14690 79725955
Reperfusion injury 66.70 50.97 11 3732 190 79740455
Post procedural complication 66.63 50.97 29 3714 23800 79716845
Coagulation time shortened 65.21 50.97 12 3731 400 79740245
Cardiogenic shock 64.99 50.97 34 3709 41880 79698765
Chest pain 60.20 50.97 70 3673 282234 79458411
Oesophageal ulcer haemorrhage 54.42 50.97 11 3732 604 79740041
Hypotension 52.19 50.97 82 3661 440235 79300410
International normalised ratio increased 51.90 50.97 38 3705 84683 79655962
Cardio-respiratory arrest 51.89 50.97 42 3701 108468 79632177
Pharyngeal haemorrhage 51.31 50.97 12 3731 1304 79739341

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AE06 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct thrombin inhibitors
FDA MoA N0000009963 Thrombin Inhibitors
FDA EPC N0000175518 Direct Thrombin Inhibitor
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
FDA EPC N0000175980 Anti-coagulant
CHEBI has role CHEBI:50249 anticoagulants
CHEBI has role CHEBI:65232 thrombin inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008
Unstable Angina Pectoris during PTCA indication
Acute coronary syndrome off-label use 394659003
Intracranial hemorrhage contraindication 1386000
Bleeding contraindication 131148009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.51 acidic
pKa3 3.89 acidic
pKa4 4.04 acidic
pKa5 4.21 acidic
pKa6 4.49 acidic
pKa7 9.65 acidic
pKa8 11.93 acidic
pKa9 12.59 acidic
pKa10 12.84 acidic
pKa11 13.06 acidic
pKa12 13.08 acidic
pKa13 13.4 acidic
pKa14 13.64 acidic
pKa15 13.69 acidic
pKa16 13.81 acidic
pKa17 13.99 acidic
pKa18 10.75 Basic
pKa19 8.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prothrombin Enzyme INHIBITOR Ki 8.60 IUPHAR CHEMBL

External reference:

IDSource
4021268 VUID
N0000148708 NUI
D03136 KEGG_DRUG
285044 RXNORM
C0168273 UMLSCUI
CHEBI:59173 CHEBI
CHEMBL2103749 ChEMBL_ID
CHEMBL3989957 ChEMBL_ID
DB00006 DRUGBANK_ID
C074619 MESH_SUPPLEMENTAL_RECORD_UI
6470 IUPHAR_LIGAND_ID
7282 INN_ID
TN9BEX005G UNII
16129704 PUBCHEM_CID
15879 MMSL
234768 MMSL
41019 MMSL
d04744 MMSL
129498009 SNOMEDCT_US
400610005 SNOMEDCT_US
4021268 VANDF
009031 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bivalirudin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9572 INJECTION 250 mg INTRAVENOUS NDA 25 sections
Bivalirudin in 0.9% Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9576 INJECTION 500 mg INTRAVENOUS NDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 28 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 28 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 28 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0409-8300 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 28 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections
Angiomax HUMAN PRESCRIPTION DRUG LABEL 1 0781-3447 INJECTION 250 mg INTRAVENOUS NDA 25 sections
Angiomax HUMAN PRESCRIPTION DRUG LABEL 1 0781-3447 INJECTION 250 mg INTRAVENOUS NDA 25 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 0781-9158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 16729-275 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 42023-622 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 26 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 52958-034 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 23 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 55111-652 INJECTION 250 mg INTRACAVERNOUS ANDA 25 sections
BIVALIRUDIN Human Prescription Drug Label 1 55150-210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
BIVALIRUDIN Human Prescription Drug Label 1 55150-210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
BIVALIRUDIN Human Prescription Drug Label 1 55150-210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 27 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 63323-562 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 27 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 67457-256 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70436-025 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 250 mg INTRAVENOUS ANDA 26 sections
Angiomax RTU HUMAN PRESCRIPTION DRUG LABEL 1 70511-141 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 25 sections
Bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 70860-402 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
Bivalirudin RTU HUMAN PRESCRIPTION DRUG LABEL 1 70860-403 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 26 sections
BIVALIRUDIN HUMAN PRESCRIPTION DRUG LABEL 1 71288-427 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS ANDA 26 sections
bivalirudin HUMAN PRESCRIPTION DRUG LABEL 1 72572-035 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 250 mg INTRAVENOUS NDA authorized generic 25 sections